Skip to main
CYTK
CYTK logo

Cytokinetics (CYTK) Stock Forecast & Price Target

Cytokinetics (CYTK) Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Cytokinetics Inc is positioned for strong growth due to promising results from its trials, particularly with omecamtiv and aficamten, which showcase effective treatment in high-risk heart failure patients and leverage partnerships with established companies like Bayer and Sanofi to enhance global market potential. The firm has demonstrated its commitment to achieving significant clinical and regulatory milestones in the near term, supported by its robust funding and strategic Vision 2030 plan. Additionally, its focus on developing innovative muscle activators and inhibitors for serious diseases highlights the company's potential for substantial impact in the biopharmaceutical space, indicative of a favorable outlook.

Bears say

Cytokinetics faces significant risks that could negatively impact its financial outlook, including the potential for failed or inconclusive clinical trials, which could hinder the progress of its drug development. Additionally, the company may struggle with regulatory and commercial success, which could limit its ability to bring treatments to market and generate revenue. Lastly, there are concerns regarding the company's ability to secure adequate funding, which is crucial for advancing its investigational medicines through the development process.

Cytokinetics (CYTK) has been analyzed by 30 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cytokinetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cytokinetics (CYTK) Forecast

Analysts have given Cytokinetics (CYTK) a Buy based on their latest research and market trends.

According to 30 analysts, Cytokinetics (CYTK) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cytokinetics (CYTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.